INO
Price
$1.65
Change
-$0.04 (-2.37%)
Updated
Feb 4, 02:52 PM (EDT)
Capitalization
116.11M
Intraday BUY SELL Signals
KROS
Price
$17.87
Change
-$0.60 (-3.25%)
Updated
Feb 4, 02:55 PM (EDT)
Capitalization
562.71M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INO vs KROS

Header iconINO vs KROS Comparison
Open Charts INO vs KROSBanner chart's image
Inovio Pharmaceuticals
Price$1.65
Change-$0.04 (-2.37%)
Volume$588
Capitalization116.11M
Keros Therapeutics
Price$17.87
Change-$0.60 (-3.25%)
Volume$300
Capitalization562.71M
INO vs KROS Comparison Chart in %
View a ticker or compare two or three
VS
INO vs. KROS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a StrongBuy and KROS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (INO: $1.69 vs. KROS: $18.47)
Brand notoriety: INO: Notable vs. KROS: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 76% vs. KROS: 48%
Market capitalization -- INO: $116.11M vs. KROS: $562.71M
INO [@Biotechnology] is valued at $116.11M. KROS’s [@Biotechnology] market capitalization is $562.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).

  • INO’s TA Score: 4 bullish, 7 bearish.
  • KROS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KROS is a better buy in the short-term than INO.

Price Growth

INO (@Biotechnology) experienced а +10.46% price change this week, while KROS (@Biotechnology) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

KROS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KROS($563M) has a higher market cap than INO($116M). INO YTD gains are higher at: -2.874 vs. KROS (-9.283). KROS has higher annual earnings (EBITDA): 68.8M vs. INO (-105.08M). KROS has more cash in the bank: 693M vs. INO (50.8M). INO has less debt than KROS: INO (10M) vs KROS (17.4M). KROS has higher revenues than INO: KROS (247M) vs INO (182K).
INOKROSINO / KROS
Capitalization116M563M21%
EBITDA-105.08M68.8M-153%
Gain YTD-2.874-9.28331%
P/E RatioN/A11.84-
Revenue182K247M0%
Total Cash50.8M693M7%
Total Debt10M17.4M57%
FUNDAMENTALS RATINGS
INO vs KROS: Fundamental Ratings
INO
KROS
OUTLOOK RATING
1..100
965
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10069
PRICE GROWTH RATING
1..100
6344
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (59) in the Medical Specialties industry is in the same range as KROS (59) in the null industry. This means that INO’s stock grew similarly to KROS’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as KROS (100) in the null industry. This means that INO’s stock grew similarly to KROS’s over the last 12 months.

KROS's SMR Rating (69) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that KROS’s stock grew similarly to INO’s over the last 12 months.

KROS's Price Growth Rating (44) in the null industry is in the same range as INO (63) in the Medical Specialties industry. This means that KROS’s stock grew similarly to INO’s over the last 12 months.

KROS's P/E Growth Rating (99) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that KROS’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOKROS
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INO
Daily Signal:
Gain/Loss:
KROS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CWXZF7.340.24
+3.45%
Doman Building Materials Group Ltd.
TNABF3.420.06
+1.63%
Tenaga Nasional Berhad
BUHPF5.65N/A
N/A
Bumrungrad Hospital Public Co., Ltd.
VEEMF0.48N/A
N/A
VEEM LTD.
MWAI0.52N/A
N/A
MedwellAI, Inc.

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-0.59%
AXON - INO
53%
Loosely correlated
-1.89%
ARRY - INO
52%
Loosely correlated
+1.71%
RARE - INO
44%
Loosely correlated
+0.16%
ALNY - INO
42%
Loosely correlated
+3.74%
BTAI - INO
39%
Loosely correlated
-0.63%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.38%
INO - KROS
53%
Loosely correlated
-0.59%
AXON - KROS
43%
Loosely correlated
-1.89%
CLDX - KROS
41%
Loosely correlated
+2.07%
ALT - KROS
39%
Loosely correlated
-1.44%
SPHDF - KROS
38%
Loosely correlated
N/A
More